Price Crosses Moving Average
|Bid||17.75 x 800|
|Ask||18.24 x 900|
|Day's Range||17.52 - 18.63|
|52 Week Range||4.14 - 22.07|
|Beta (5Y Monthly)||2.59|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||31.67|
Data from Phase 3 LIBERTY program show improvement in patient-reported outcomes in addition to improvement in hemoglobin levels in anemic womenDetailed data from ovulation.
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]
The COVID-19 pandemic has decimated the U.S. economy, yet the stock market is alive and well. Against the backdrop of a recession, the market actually had its strongest quarter in over 20 years, with the S&P 500 notching its largest quarterly gain since the last quarter of 1998, surging 20%. As for the NASDAQ, it climbed 31% higher during the quarter, marking its best quarterly performance since Q4 1999.While certainly volatile, the quarter saw investors take an optimistic approach due to reopening efforts and unprecedented stimulus packages. That being said, going forward into Q3, plenty of uncertainty is lingering over Wall Street. So, how are investors supposed to lock in on compelling plays? The Street’s pros can provide some much-needed inspiration, namely those from investment firm Goldman Sachs.Taking all of this into consideration, we used TipRanks’ database to learn more about three stocks backed by Goldman Sachs. As it turns out, the firm’s analysts projecting more than 30% upside potential for each. The rest of the Street is on the same page, with each ticker earning a “Strong Buy” consensus rating.Myovant Sciences (MYOV)Combining purpose-driven science, empowering medicines and transformative advocacy, Myovant Sciences wants to change the treatment landscape for both women and men. On the heels of its recent data readout, Goldman Sachs is even more optimistic about this healthcare name.Covering this stock for the firm, five-star analyst Paul Choi tells clients that a key component of his bullish thesis is its relugolix asset. MYOV recently published positive Phase 3 data from its SPIRIT 1 study evaluating a once-daily relugolix combination therapy in women with endometriosis. This data supported the data from the previously reported SPIRIT 2 study.Looking more closely at the results, 74.5% of patients saw a clinically meaningful reduction in dysmenorrhea compared to 26.9% of women in the placebo group, with the placebo-adjusted difference landing at 47.6%. Choi notes that Orilissa, the currently approved therapy for moderate to severe pain caused by endometriosis, demonstrated a 27%/21% (two trials) placebo-adjusted difference for its 150 mg once-daily therapy and a difference of 56%/50% for its 200 mg twice daily dose.However, Orilissa can cause hypoestrogenic symptoms including hot flashes and loss of bone mineral density. Choi pointed out, “To avoid this, physicians can co-prescribe progestin and/or estradiol (add-back therapy). However, physicians emphasized that the once-daily, fixed-dose pill containing relugolix and add-back therapy would more readily convince a physician to prescribe it instead as the dosing schedule of Orilissa can be confusing, even for the prescriber.” MYOV’s candidate produced significantly fewer hot flashes, making Choi even more confident.“In addition to the side effect profile and simple dosing schedule, physicians called out that many OBGYN offices were not equipped to handle the prior authorizations required for use. MYOV has focused efforts here to ensure that the proper tools are delivered to support prior auth requirements,” Choi added.As updated data from the Phase 3 open-label extension study (LIBERTY) evaluating relugolix combination therapy in women with uterine fibroids (UF) was also promising, the deal is sealed for Choi. To this end, the analyst maintained a Buy rating along with a $28 price target, suggesting 40% upside potential. (To watch Choi’s track record, click here) Most other analysts also take a bullish approach. MYOV’s Strong Buy consensus rating breaks down into 3 Buys and only 1 Hold. Additionally, the $27.33 average price target puts the upside potential at 36%. (See MYOV stock analysis on TipRanks)Southwest Airlines (LUV)It’s no secret that COVID-19 has dealt the travel industry a swift blow. That being said, as passenger volumes have started to recover from the low point hit in April and market trends improve, Goldman Sachs is turning more bullish on Southwest Airlines.Representing the firm, analyst Catherine O’Brien doesn’t dispute the fact that since LUV was added to the Americas Sell List on February 19, shares have plummeted 40% compared to the S&P 500’s 8% loss.Singing a different tune now, O’Brien argues that given the airline industry’s focus on driving a rebound from the pandemic-induced lows, “Southwest’s primarily domestic network and industry leading balance sheet will drive a faster-than-industry recovery in profitability.”Specifically looking at the latter, the analyst commented, “Additionally, given that liquidity remains a concern for the industry, balance sheet strength is currently of even more importance than it typically is, in our view.”It should also be noted that LUV shares have historically experienced less turbulence than other players in the space. Therefore, while it boasts less upside potential than some of the firm’s other Buy-rated stocks, the level of upside here is enough to convince O’Brien to stand squarely in the bull camp.As a result, O’Brien just gave LUV a thumbs up, upgrading her rating from Sell to Buy. If that wasn’t enough, the price target also gets a lift, from $35 to $47. Should the target be met, a twelve-month gain of 37% could be in store. (To watch O’Brien’s track record, click here) In general, other analysts also like what they’re seeing. 11 Buys and 3 Holds add up to a Strong Buy consensus rating. Based on the $42.25 average price target, the upside potential comes in at 23%. (See LUV stock analysis on TipRanks)ServiceNow (NOW)As for Goldman Sachs’ third pick, ServiceNow offers software that delivers digital workflows designed to improve productivity. Given the strength of its technology, the firm sees big things in store for the tech company.After looking at the space as a whole, four-star analyst Christopher Merwin goes so far as to deem NOW a best idea. Expounding on this, he wrote, “We believe the resiliency of the sector throughout COVID underscores the criticality of many software categories as businesses adjust for more distributed workforces and therefore require modernized cloud systems. With sector multiples at all-time highs, we favor stocks where we see compelling relative value.”According to Merwin, NOW is set to be a “key beneficiary of digital transformations as enterprise customers increasingly focus on leveraging a select few strategic platforms that can deliver could-based solutions with ease, agility, and integrations.” Citing its product development, the analyst believes its approach is “best-in-class", with the company continuing to expand into new areas like financial operations management and DevOps.“We believe this rich product roadmap, and ongoing momentum for ITSM, ITOM, HR, and CSM, will all help to sustain 28%-plus subscription revenue growth through FY22E,” Merwin commented. Going forward, its efforts to re-invest in new products in order to increase the addressable market and runway for growth should help NOW reach its long-term revenue target of $10 billion, in the analyst’s opinion.Merwin added, “As software valuations continue to move higher across the space, we believe NOW stands out as an attractively valued stock - particularly on a growth-adjusted FCF, trading at 45.5x our CY21E FCF, relative to FCF growth expectations of 35%.”It should come as no surprise, then, that Merwin stayed with the bulls. In addition to keeping a Buy rating on the stock, the analyst gave the price target a boost, from $403 to $538, which brings the upside potential to 33%. (To watch Merwin’s track record, click here) Do other analysts agree with Merwin? As it turns out, most do. With 19 Buys and 4 Holds assigned in the last three months, the word on the Street is that NOW is a Strong Buy. However, at $396.32, the average price target does indicate 3% downside potential. (See ServiceNow stock-price forecast on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
CHICAGO, Ill.; SAN MATEO, Calif.; LOS ANGELES, Calif.; and BASEL, Switzerland, June 30, 2020 (GLOBE NEWSWIRE) -- BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences (NYSE: MYOV) today announced the launch of Forward Momentum, a cross-sector coalition working on innovative projects to increase diversity in research and develop new digital resources for men with prostate cancer. Prostate cancer is the second most prevalent form of cancer and second leading cause of cancer death in men in the U.S. More than 3 million men have been diagnosed with prostate cancer in the U.S. and more than 33,000 deaths are expected in 2020, with Black men twice as likely to die from the disease.
Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.
Shares of Myovant Sciences Ltd. gained 7% in premarket trading on Tuesday after the drugmaker said a late-stage clinical trial for its experimental endometriosis drug hit its primary and secondary endpoints. The relugolix combination therapy helped reduce pain among the studied segment of patients with endometriosis. "Women need and deserve treatment options beyond surgery, and these data indicate relugolix combination therapy has the potential to substantially reduce pain while improving function and activities of daily living and decreasing the proportion of women on opioids," Dr. Eric Brown, an obstetrician-gynecologist and an investigator for the study, said in a news release. The company's stock is up 12.8% year-to-date, while the S&P 500 is down 3.5%. C
Co-primary endpoints met with response rates of 74.5% for dysmenorrhea (menstrual pain) and 58.5% for non-menstrual pelvic pain (p-values < 0.0001)Women receiving relugolix.
Sumitovant Biopharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review, the New Drug Application (NDA) submitted by Myovant Sciences (MYOV), for once-daily, oral relugolix (120 mg) for the treatment of men with advanced prostate cancer. “We are delighted that the FDA has accepted for Priority Review our New Drug Application for relugolix, bringing us one step closer to providing a one pill, once-a-day potential new treatment option to men with advanced prostate cancer,” said Lynn Seely, M.D., chief executive officer of Myovant Sciences.
BASEL, Switzerland, June 22, 2020 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will host a.
Myovant Sciences (MYOV), a healthcare company focused on redefining care for women and for men, today announced that its New Drug Application (NDA) for once-daily, oral relugolix (120 mg) for the treatment of men with advanced prostate cancer has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA). “We are delighted that the FDA has accepted for Priority Review our New Drug Application for relugolix, bringing us one step closer to providing a one pill, once a day potential new treatment option to men with advanced prostate cancer,” said Lynn Seely, M.D., chief executive officer of Myovant Sciences.
Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.
Sumitovant Biopharma Ltd. announced today that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitovant family of companies, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its once-daily relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.
If approved, relugolix combination tablet would be the first once-daily, oral treatment for women with heavy menstrual bleeding associated with uterine fibroids in the U.S. BASEL, Switzerland, June 01, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (MYOV), a healthcare company focused on redefining care for women and for men, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its once-daily relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg) for the treatment of women with heavy menstrual bleeding associated with uterine fibroids. “An estimated five million women in the U.S. suffer from symptoms of uterine fibroids, which may include heavy menstrual bleeding, pain, and anemia – yet effective non-invasive treatment options are very limited,” said Lynn Seely, M.D., chief executive officer of Myovant Sciences.
Sumitovant Biopharma Ltd. announced that Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, and one of five healthcare companies in the Sumitovant family of companies, today had additional results from its Phase 3 HERO study of once-daily, oral relugolix (120 mg) in men with advanced prostate cancer presented orally at the American Society of Clinical Oncology (ASCO)'s ASCO20 Virtual Scientific Program and simultaneously published in the New England Journal of Medicine (NEJM). The data expand on earlier findings from the HERO study, demonstrating the superiority of relugolix to leuprolide acetate across multiple endpoints, and further show that treatment with relugolix was associated with a lower risk of major adverse cardiovascular events compared to leuprolide acetate.
Myovant Sciences (MYOV), a healthcare company focused on redefining care for women and for men, today announced additional results from its Phase 3 HERO study of once-daily, oral relugolix (120 mg) in men with advanced prostate cancer in an oral presentation at the American Society of Clinical Oncology (ASCO)’s ASCO20 Virtual Scientific Program and simultaneous publication in the New England Journal of Medicine (NEJM). The data expand on earlier findings from the HERO study, demonstrating the superiority of relugolix to leuprolide acetate across multiple endpoints, and further show that treatment with relugolix was associated with a lower risk of major adverse cardiovascular events compared to leuprolide acetate.
- Co-primary endpoints and six key secondary endpoints met in Phase 3 SPIRIT 2 study in women with endometriosis, with results from the Phase 3 SPIRIT 1 study expected in the.
BASEL, Switzerland, May 14, 2020 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it will present.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
* Insider buying can be an encouraging signal for potential investors. * A couple of biotech stocks saw some notable insider buying last week. * Some of these insiders made return trips to the buy window.Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly during periods of uncertainty.Insiders continued to add shares despite overall market volatility and global economic gloom. Here are some of the most noteworthy insider purchases reported in the past week.Immunomedics An Immunomedics, Inc. (NASDAQ: IMMU) director took advantage of a common stock offering to add 1.75 million shares. At the offering price of $28.50 per share, that cost the director almost $49.88 million and raised the stake to 26.25 million shares. Shares outstanding number fewer and 180 million.Immunomedics stock ended last week's trading at $30.38 per share, so the purchase seems well timed. The share price is up more than 157% since its year-to-date low last month.See Also: Elon Musk Says Tesla's Stock Price Is Too High, Tweets About Freedom, Gene Wilder And MoreMyovant Sciences Myovant Sciences Ltd (NYSE: MYOV) saw 10% owner Sumitomo Chemical purchase about 190,500 shares of this London-based biopharmaceutical company last week at prices averaging about $12.05 apiece. That totaled almost $2.30 million. Note that Myovant's parent is a subsidiary of Sumitomo, which frequently has been buying shares since establishing a Rule 10b5-1 stock trading plan during the market's pandemic selling panic in mid-March.Myovant stock ended the week trading at $11.15, below the above purchase price. However, shares are still up more than 68% from their year-to-date low in March.Simply Good Foods A director at Simply Good Foods Co (NASDAQ: SMPL) returned to the buy window last week. That director bought more than 87,800 shares at prices ranging from $16.76 to $17.00, totaling over $1.48 million. The director and seven others were purchasing shares throughout April.Simply Good Foods stock popped more than 3% in the past week and closed most recently at $18.35 a share. That is well above the director's latest purchase price range.Cincinnati Financial A pair of Cincinnati Financial Corporation (NASDAQ: CINF) directors shelled out $72.25 to $72.51 per share for 5,500 shares altogether of this property casualty insurance provider. That cost them more than $398,200, and it came in the wake of posting earnings that fell short of Wall Street expectations.The latest close at $60.95 per share is well below the purchase price range above, and it came after the shares hit a 52-week low of $60.00 on Friday. The stock is down about 42% year to date, while the S&P 500 is less than 10% lower.In addition, note that there was some amount of insider buying at AGNC Investment Corp (NASDAQ: AGNC), Sterling Bancorp (NYSE: STL) and Webster Financial Corporation (NYSE: WBS) last week as well.Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter.See more from Benzinga * Notable Insider Buys Of The Past Week: JPMorgan, Huntington Ingalls And More * Notable Insider Buys In The Past Week: Carnival, MGM And More(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Myovant Sciences (MYOV), a healthcare company focused on redefining care for women’s health and prostate cancer, today announced that the journal Obstetrics & Gynecology has published three abstracts detailing additional efficacy and safety findings from the Phase 3 LIBERTY 1 and 2 studies of relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with heavy menstrual bleeding associated with uterine fibroids. The abstracts were originally accepted for presentation in oral and poster sessions at the American College of Obstetricians and Gynecologists (ACOG) 2020 Annual Clinical and Scientific Meeting, which was cancelled due to the COVID-19 pandemic.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Arvinas Inc (NASDAQ: ARVN) * Exelixis, Inc. (NASDAQ: EXEL) * GenMark Diagnostics, Inc (NASDAQ: GNMK) * Keros Therapeutics Inc (NASDAQ: KROS) * Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) * Moderna Inc (NASDAQ: MRNA) * OraSure Technologies, Inc. (NASDAQ: OSUR) * Repro-Med Systems, Inc. (NASDAQ: KRMD) * Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 21) * Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC)(announced pricing of $20 million common stock offering) * Nabriva Therapeutics PLC - ADR (NASDAQ: NBRV) * Viveve Medical Inc (NASDAQ: VIVE)Stocks In Focus Novartis' Cell Therapy Gets Regenerative Medicine Advanced Therapy Designation For Follicular Lymphoma Novartis AG (NYSE: NVS) said the FDA granted Regenerative Medicine Advanced Therapy designation to Kymriah for an investigational new indication to treat patients with relapsed or refractory follicular lymphoma. Kymriah is a CAR-T cell therapy and has already been approved for pediatric and young adult acute lymphoblastic leukemia, and adult diffuse large B-cell lymphoma.Actinium Prices Common Stock Offering at Discount Actinium Pharmaceuticals Inc (NYSE: ATNM) said it has priced its previously-announced underwritten public offering of 183.33 million shares at 15 cents per share. The company expects to raise gross proceeds of $27.5 million from the offering.The company said it intends to use the net proceeds to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate, Iomab-B, and support its BLA filing, among other things.The stock was slumping 27.94% to 17 cents in pre-market trading Wednesday.Immunic's Antiviral Investigational Assets Found Effective Against Coronavirus In Animal Studies Immunic Inc (NASDAQ: IMUX) reported that IMU-838, its lead asset has successfully demonstrated preclinical activity against SARS-CoV-2. More specifically, IMU-838 was observed to inhibit replication of clinical isolates of SARS-CoV-2 associated with COVID-19, the company said.The company said these positive results have encouraged it to prepare a clinical development program for IMU-838 as a potential treatment option for patients with COVID-19 and potential other, future viral pandemics.In premarket trading Wednesday, the stock was jumping 88.08% to $16.10. BioNTech, Pfizer Get German Regulatory Nod For Human Testing Of COVID-19 Vaccine Candidate BioNTech SE - ADR (NASDAQ: BNTX) and Pfizer Inc. (NYSE: PFE) said the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 clinical trial for BioNTech's BNT162 vaccine program to prevent COVID-19 infection. The companies are awaiting FDA nod to begin human testing in the U.S.View more earnings on GILDIn pre-market trading, BioNTech shares were soaring 52.15% to $64.30 and Pfizer was seen adding 5.56% to $37.60.Quest Begins Offering Antibody Testing For Coronavirus Quest Diagnostics Inc (NYSE: DGX) said it has begun to perform antibody testing for coronavirus using blood samples. The company already gives healthcare providers access to its molecular diagnostic laboratory testing.Gilead Strikes Immuno-oncology And Cell Therapy Collaboration With oNKo-innate Gilead Sciences, Inc. (NASDAQ: GILD), its Kite unit and oNKo-innate announced a 3-year cancer immunotherapy research collaboration to support the discovery and development of next-gen drug and engineered cell therapies focus on natural killer, or NK, cells.oNKo-innate will run screens to identify and validate targets to seed internal Gilead immuno-oncology discovery programs, while for Kite, oNKo will create and evaluate NK constructs for Kite's development of next-generation cell therapies.The stock was gaining 2.15% to $80.22 in pre-market trading.VBI Vaccines Announces Secondary Offering Of Common Stock VBI Vaccines Inc (NASDAQ: VBIV) announced that it has commenced an underwritten public offering of its common shares. The company said it intends to use the net proceeds to support the regulatory filings, pre- commercialization, and launch planning activities for Sci-B-Vac in the U.S., Europe, and Canada, for the continued advancement of its pipeline programs, and for general corporate purposes.In pre-market trading, the stock was slumping 30.13% to $1.09.met its co-primary efficacy endpoints and six key secondary endpoints. In addition, relugolix combination therapy was generally well-tolerated including minimal bone mineral density loss over 24 weeks.Myovant Reports Positive Results For Latestage Study of Drug to Treat Endometriosis-Related Pain Myovant Sciences Ltd (NYSE: MYOV) announced results from the Phase 3 SPIRIT 2 study of once-daily relugolix combination therapy in women with pain associated with endometriosis, which showed the study met its co-primary efficacy endpoints and six key secondary endpoints.In pre-market trading, shares were adding 7.08% to $12.40.On The Radar Earnings * Biogen Inc (NASDAQ: BIIB) (before the market opens) * Quest Diagnostics (before the market opens)See more from Benzinga * The Daily Biotech Pulse: Moderna Secures 3M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement * Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.